Anti-EGFR x Anti-IGF1R Bispecific Antibody (IgG-IgG) (BSIG-H323)

Anti-EGFR x Anti-IGF1R Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-EGFR and anti-IGF1R parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can bind and inactivate two receptors simultaneously. It is designed for the research of Colorectal cancer; Cervical cancer; Breast cancer; Pancreatic cancer therapy.

Datasheet

Specifications

Targets

EGFR & IGF1R

Type

IgG-IgG

Species Reactivity

Human

Target 1

EGFR

Host Animal 1

Human

Target 2

IGF1R

Host Animal 2

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Colorectal cancer; Cervical cancer; Breast cancer; Pancreatic cancer

Targets

Target 1

EGFR

Gene ID

1956

UniProt ID

P00533

Alternative Names

EGFR; epidermal growth factor receptor; ERBB; HER1; mENA; ERBB1; PIG61; NISBD2; proto-oncogene c-ErbB-1; cell growth inhibiting protein 40; erb-b2 receptor tyrosine kinase 1; cell proliferation-inducing protein 61; receptor tyrosine-protein kinase erbB-1; avian erythroblastic leukemia viral (v-erb-b) oncogene homolog

Target 2

IGF1R

Gene ID

3480

UniProt ID

P08069

Alternative Names

IGF1R; insulin-like growth factor 1 receptor; IGFR; CD221; IGFIR; JTK13; IGF-I receptor; soluble IGF1R variant 1; soluble IGF1R variant 2; insulin-like growth factor I receptor

Welcome! For price inquiries, we will get back to you as soon as possible.

To order, please email

INQUIRY

Online Inquiry

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email:

Europe
Heidenkampsweg 58, 20097 Hamburg, Germany
Tel: 44-207-097-1828
Email: